NAGIOS: RODERIC FUNCIONANDO

Role of serum interleukin-6 in deciding therapy for multidrug resistant oral lichen planus

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Role of serum interleukin-6 in deciding therapy for multidrug resistant oral lichen planus

Mostra el registre parcial de l'element

dc.contributor.author Goel, Sinny es
dc.contributor.author Marwah, Akanksha es
dc.contributor.author Kaushik, Smita es
dc.contributor.author Garg, Vijay K. es
dc.contributor.author Gupta, Sunita es
dc.date.accessioned 2015-11-23T13:53:19Z
dc.date.available 2015-11-23T13:53:19Z
dc.date.issued 2015 es
dc.identifier.citation Goel, Sinny ; Marwah, Akanksha ; Kaushik, Smita ; Garg, Vijay K. ; Gupta, Sunita. Role of serum interleukin-6 in deciding therapy for multidrug resistant oral lichen planus . En: Journal of Clinical and Experimental Dentistry, 2015, Vol. 7, No. 4: 477-482 es
dc.identifier.uri http://hdl.handle.net/10550/48354
dc.description.abstract Background: Oral lichen planus (OLP) is a T cell mediated immune response. T cells locally present in the involved tissues release cytokines like interleukin-6 (IL-6), which contributes to pathogenesis of OLP. Also IL-6 has been associated with multidrug resistance protein (MRP) expression by keratinocytes. Correspondingly, upregulation of MRP was found in OLP. We conducted this study to evaluate the effects of various drugs on serum IL-6 in OLP; and correlation of these effects with the nature of clinical response and resistance pattern seen in OLP lesions with various therapeutic modalities. Thus we evaluated the role of serum IL-6 in deciding therapy for multidrug resistant OLP. Material and Methods: Serum IL-6 was evaluated in 42 erosive OLP (EOLP) patients and 10 normal mucosa and 10 oral squamous cell carcinoma cases using ELISA technique. OLP patients were randomly divided into 3 groups of 14 patients each and were subjected to Pimecrolimus local application, oral Mycophenolate Mofetil (MMF) and Methotrexate (MTX) alongwith Pimecrolimus local application. IL-6 levels were evaluated before and after treatment. Results: Serum IL-6 levels were raised above 3pg/ml in 26.19% erosive OLP (EOLP) cases (mean- 3.72±8.14). EOLP (5%) cases with IL-6 levels above 5pg/ml were resistant in MTX group. However significant decrease in serum IL-6 corresponding with the clinical resolution was seen in MMF group. Conclusions: Significantly raised IL-6 levels in EOLP reflect the chronic inflammatory nature of the disease. As serum IL-6 levels significantly decreased in MMF group, correspondingly no resistance to treatment was noted. However with MTX there was no significant decrease in IL-6 and resistance to treatment was noted in some, especially plaque type lesions. Thus IL-6 can be a possible biomarker in deciding the best possible therapy for treatment resistant OLP. en_US
dc.subject Odontología es
dc.subject Ciencias de la salud es
dc.title Role of serum interleukin-6 in deciding therapy for multidrug resistant oral lichen planus es
dc.type journal article es_ES
dc.subject.unesco UNESCO::CIENCIAS MÉDICAS es
dc.type.hasVersion VoR es_ES

Visualització       (390.6Kb)

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre parcial de l'element

Cerca a RODERIC

Cerca avançada

Visualitza

Estadístiques